최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of applied toxicology : JAT, v.36 no.1, 2016년, pp.140 - 150
Healing, Guy (AstraZeneca, Drug Safety and Metabolism, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK) , Sulemann, Tabassum (AstraZeneca, Pharmaceutical Development, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK) , Cotton, Peter (AstraZeneca, Drug Safety and Metabolism, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK) , Harris, Jayne (AstraZeneca, Drug Safety and Metabolism, 310 Darwin Building, Science Park, Cambridge, CB40 0WG, UK) , Hargreaves, Adam (AstraZeneca, Drug Safety and Metabolism, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK) , Finney, Rowena (AstraZeneca, Drug Safety and Metabolism, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK) , Kirk, Sarah (AstraZeneca, Discovery Sciences, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK) , Schramm, Carolin (Ast) , Garner, Clare , Pivette, Perrine , Burdett, Lisa
AbstractPotential new drugs are assessed in pre‐clinical in vivo studies to determine their safety profiles. The drugs are formulated in vehicles suitable for the route of administration and the physicochemical properties of the drug, aiming to achieve optimal exposure in the test species. The...
Anonymous . 1987 . Final report on the safety assessment of oleic acid, lauric acid, palmitic acid, myristic acid, and stearic acid . J. Am. Coll. Toxicol. 6 : 321 – 401 .
Brewster MA , Loftsson T . 2007 . Cyclodextrins as pharmaceutical solubilizers . Adv. Drug Deliver. Rev. 59 : 645 – 666 .
Delongeas JL , Vermeil de Conchard G , Beamonte A , Bertheux H , Spire C , Maisonneuve C , Becourt‐Lhote N , Goldfain‐Blanc F , Claude N . 2010 . Assessment of Labrasol®/Labrafil®/Transcutol® (4/4/2, v/v/v) as non‐clinical vehicle for poorly water‐soluble compounds after 4‐weeks oral toxicity study in Wistar rats . Regul. Toxicol. Pharm. 57 : 284 – 290 .
Duvinage C , Millecamps S , Sagnier A , Guffroy M , Sarsat J‐P , Belin V . 1996 . One‐month intravenous toxicity studies of poloxamer 188 in male Sprague‐Dawley rats and in beagle dogs . Toxicol. Lett. 88 : 101 .
European Medicines Agency (EMA) . Committee for Medicinal Products for Human Use (CHMP). 2013 . Guideline on the Use of Phthalates as Excipients in Human Medicinal Products – Draft . EMA/CHMP/SWP/362974/2012.
Gad SC , Cassidy CD , Aubert N , Spainhour B , Robbe H . 2006 . Nonclinical vehicles use in studies by multiple routes in multiple species . Int. J. Toxicol. 25 : 499 – 521 .
Gad SC . 2009 . Appendix E: Common vehicles for nonclinical evaluation of therapeutic agents . In Drug Safety Evaluation , 2nd edn , Gad SC (ed). John Wiley and Sons : New York ; 1140 – 1160 .
Gopinathan S , O'Neill E , Rodriguez LA , Champ R , Phillips M , Nouraldeen A , Wendt M , Wilson AGE , Kramer JA . 2013 . In vivo toxicology of excipients commonly employed in drug discovery in rats . J. Pharm. Toxicol. Methods. 68 : 284 – 295 .
Gould S , Scott R . 2005 . Hydroxypropyl‐beta‐cyclodextrin: A toxicology review . Food Chem. Toxicol. 43 : 1451 – 1459 .
Hamid KA , Katsumi H , Sakane T , Yamamoto A . 2009 . The effects of common solubilising agents on the intestinal membrane barrier functions and membrane toxicity in rats . Int. J. Pharmaceutics 379 : 100 – 108 .
Hermansky SJ , Neptun DA , Loughran KA , Leung HW . 1995 . Effects of polyethylene glycol 400 (PEG 400) following 13 weeks of gavage treatment in Fischer‐344 rats . Fd. Chem. Toxic. 33 : 139 – 149 .
Humberstone AJ , Charman WN . 1997 . Lipid‐based vehicles for the oral delivery of poorly soluble drugs . Adv. Drug Deliver. Rev. 25 : 103 – 128 .
ICH M3(R2) . 2009 . Non‐Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals .
Kitagawa H , Yano H , Fukuda Y . 1973 . Chronic toxicity of hydroxypropylmethylcellulose phthalate in rats . Pharmacometrics 7 : 689 – 701 .
LaKind JS , McKenna EA , Hubner RP , Tardiff RG . 1999 . A review of the comparative mammalian toxicity of ethylene glycol and propylene glycol . Cr. Rev. Toxicol. 29 : 331 – 365 .
Leuner C , Dressman J . 2000 . Improving drug solubility for oral delivery using solid dispersions . Eur. J. Pharm. Biopharm. 50 : 47 – 60 .
Li P , Zhao L , Yalkowsky SH . 1999 . Combined effect of co solvent and cyclodextrin on solubilization of nonpolar drugs . J. Pharm. Sci. 88 : 1107 – 1111 .
Loftsson T , Másson M , Brewster , ME . 2004 . Self‐association of cyclodextrins and cyclodextrin complexes . J. Pharm. Sci. 93 : 1091 – 1099 .
Lowry OH , Rosebrough NJ , Farr AL , Randall RJ . 1951 . Protein measurement with the folin phenol reagent . J. Biol. Chem. 193 : 265 – 275 .
McMartin K. 2009 . Are calcium oxalate crystals involved in the mechanism of acute renal failure in ethylene glycol poisoning? Clin. Toxicol. (Phila.) 47 : 859 – 869 .
Mullertz A , Ogbonna A , Ren S , Rades T . 2010 . New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs . J. Pharm. Pharmacol. 62 : 1622 – 1636 .
Noel PRB , Barnett KC , Davies RE , Jolly DW , Leahy JS , Mawdesley‐Thomas LE , Shillam KWG , Swuires SPF , Street AE , Tucker WC , Worden AN . 1975 . The toxicity of dimethyl sulphoxide (DMSO) for the dog, pig, rat and rabbit . Toxicology 3 : 143 – 169 .
Pestel S , Martin H‐J , Maier G‐M , Guth B . 2006 . Effect of commonly used vehicles on gastrointestinal, renal and liver function in rats . J. Pharmacol. Toxicol. Methods 54 : 200 – 214 .
Pomara C , Fiore C , E'Errico S , Riezzo I , Fineschi V . 2008 . Calcium oxalate crystals in acute ethylene glycol poisoning: A confocal laser scanning microscope study in a fatal case . Clin. Toxicol. (Phila.) 46 : 322 – 324 .
Schladt L , Ivens I , Karbe E , Ruhl‐Fehlert C , Bomhard E . 1998 . Subacute oral toxicity of tetraethylene and ethylene glycol administered to Wistar rats . Exp. Toxic. Pathol. 50 : 257 – 265 .
Schwarz W . 1990 . PVP: A Critical Review of the Kinetics and Toxicology of Polyvinylpyrrolidone (povidone) . CRC Press .
Sellers RS , Antman M , Phillips J , Khan KN , Furst SM . 2005 . Effect of miglyol 812 on rats after 4 weeks of gavage as compared with methylcellulose/twen 80 . Drug Chem. Toxicol. 28 : 423 – 432 .
Singh‐Joy SD . 2008 . Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 288, 331, 333, 334, 335, 338, 401, 402, 403 and 407, poloxamer 105 benzoate and poloxamer 182 dibenzoate as used in cosmetics . Int. J. Toxicol. 27 : 93 – 128 .
Som I , Bhatia K , Yasir M . 2012 . Status of surfactants as penetration enhancers in transdermal drug delivery . J. Pharm. Bioallied. Sci. 4 : 2 – 9 .
Stella VJ , Rajewski RA . 1997 . Cyclodextrins: their future in drug formulation and delivery . Pharm. Res. 14 : 556 – 567 .
Stokes AH , Kemp DC , Faiola B , Jordan HL , Merrill CL , Hailey JR , Brown RE , Bailey DW . 2013 . Effects of Solutol (Kolliphor) and Cremophor in Polyethylene Glycol 400 vehicle formulation in Sprague‐Dawley rats and beagle dogs . Int. J. Toxicol. 32 : 189 – 197 .
Strickley RG . 2004 . Solubilizing excipients in oral and injectable formulations . Pharm. Res. 21 : 201 – 230 .
Sullivan Jr DW , Gad SC , Julien M . 2014 . A review of the nonclinical safety of Transcutol®, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient . Food Chem. Toxicol. 72 : 40 – 50 .
Sweetana S , Akers MJ . 1996 . Solubility principles and practices for parenteral drug dosage form development . PDA J. Pharm. Sci. Technol. 50 : 330 – 342 .
Thackaberry EA , Kopytek S , Sherrat P , Trouba K , McIntyre B . 2010 . Comprehensive investigation of hydroxypropyl methylcellulose, propylene glycol, polysorbate 80 and hydroxypropyl‐beta‐cyclodextrin for use in general toxicology studies . Toxicol. Sci. 117 : 485 – 492 .
Thackaberry EA . 2013 . Vehicle selection for nonclinical oral safety studies . Expert Opin. Drug Metab. Toxicol. 9 : 1635 – 1646 .
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.